529 related articles for article (PubMed ID: 19637198)
1. The duration of TCR/pMHC interactions regulates CTL effector function and tumor-killing capacity.
Riquelme E; Carreño LJ; González PA; Kalergis AM
Eur J Immunol; 2009 Aug; 39(8):2259-69. PubMed ID: 19637198
[TBL] [Abstract][Full Text] [Related]
2. Class I- and class II-reactive TCRs coexpressed on CD4+ T cells both trigger CD4/CD8-shared and CD4-unique functions.
Asnagli H; Schmitt-Verhulst AM; Guimezanes A
J Immunol; 1997 May; 158(10):4533-42. PubMed ID: 9144464
[TBL] [Abstract][Full Text] [Related]
3. Dissecting TCR-MHC/peptide complex interactions with A2/peptide multimers incorporating tumor antigen peptide variants: crucial role of interaction kinetics on functional outcomes.
Dutoit V; Guillaume P; Cerottini JC; Romero P; Valmori D
Eur J Immunol; 2002 Nov; 32(11):3285-93. PubMed ID: 12555674
[TBL] [Abstract][Full Text] [Related]
4. Discrepancy between ELISPOT IFN-gamma secretion and binding of A2/peptide multimers to TCR reveals interclonal dissociation of CTL effector function from TCR-peptide/MHC complexes half-life.
Rubio-Godoy V; Dutoit V; Rimoldi D; Lienard D; Lejeune F; Speiser D; Guillaume P; Cerottini JC; Romero P; Valmori D
Proc Natl Acad Sci U S A; 2001 Aug; 98(18):10302-7. PubMed ID: 11517329
[TBL] [Abstract][Full Text] [Related]
5. Defective CD8+ T cell activation and cytolytic function in the absence of LFA-1 cannot be restored by increased TCR signaling.
Shier P; Ngo K; Fung-Leung WP
J Immunol; 1999 Nov; 163(9):4826-32. PubMed ID: 10528183
[TBL] [Abstract][Full Text] [Related]
6. Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo.
Prévost-Blondel A; Zimmermann C; Stemmer C; Kulmburg P; Rosenthal FM; Pircher H
J Immunol; 1998 Sep; 161(5):2187-94. PubMed ID: 9725210
[TBL] [Abstract][Full Text] [Related]
7. T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors.
Marzo AL; Lake RA; Robinson BW; Scott B
Cancer Res; 1999 Mar; 59(5):1071-9. PubMed ID: 10070965
[TBL] [Abstract][Full Text] [Related]
8. TCR alpha beta+ anti-tumor cytolytic T lymphocytes express NKR-P1 whilethe anti-tumor activity of TCR gamma delta+ T lymphocytes is not correlated to NKR-P1 expression.
Yrlid U; Petersson E; Dohlsten M; Hedlund G
Cell Immunol; 1996 Nov; 173(2):287-94. PubMed ID: 8912889
[TBL] [Abstract][Full Text] [Related]
9. Efficient T cell activation requires an optimal dwell-time of interaction between the TCR and the pMHC complex.
Kalergis AM; Boucheron N; Doucey MA; Palmieri E; Goyarts EC; Vegh Z; Luescher IF; Nathenson SG
Nat Immunol; 2001 Mar; 2(3):229-34. PubMed ID: 11224522
[TBL] [Abstract][Full Text] [Related]
10. The degree of CD8 dependence of cytolytic T cell precursors is determined by the nature of the T cell receptor (TCR) and influences negative selection in TCR-transgenic mice.
Auphan N; Curnow J; Guimezanes A; Langlet C; Malissen B; Mellor A; Schmitt-Verhulst AM
Eur J Immunol; 1994 Jul; 24(7):1572-7. PubMed ID: 8026519
[TBL] [Abstract][Full Text] [Related]
11. Protective immunity from naive CD8+ T cells activated in vitro with MHC class I binding immunogenic peptides and IL-2 in the absence of specialized APCs.
Hauser C; Zipprich F; Leblond I; Wirth S; Hügin AW
J Immunol; 1999 Jul; 163(1):330-6. PubMed ID: 10384132
[TBL] [Abstract][Full Text] [Related]
12. Antigen recognition and allogeneic tumor rejection in CD8+ TCR transgenic/RAG(-/-) mice.
Manning TC; Rund LA; Gruber MM; Fallarino F; Gajewski TF; Kranz DM
J Immunol; 1997 Nov; 159(10):4665-75. PubMed ID: 9366389
[TBL] [Abstract][Full Text] [Related]
13. Rejection of an IA+ variant line of FBL-3 leukemia by cytotoxic T lymphocytes with CD4+ and CD4-CD8- T cell receptor-alpha beta phenotypes generated in CD8-depleted C57BL/6 mice.
Yoshimura A; Shiku H; Nakayama E
J Immunol; 1993 Jun; 150(11):4900-10. PubMed ID: 8496592
[TBL] [Abstract][Full Text] [Related]
14. Characterization of anti-CD8-resistant cytolytic T lymphocytes induced by multivalent cross-linking of CD8 on precursor cells.
McCarthy SA; Kaldjian E; Singer A
J Immunol; 1989 Oct; 143(7):2112-9. PubMed ID: 2528588
[TBL] [Abstract][Full Text] [Related]
15. Tumor defense by murine cytotoxic T cells specific for peptide bound to nonclassical MHC class I.
Griffiths E; Ong H; Soloski MJ; Bachmann MF; Ohashi PS; Speiser DE
Cancer Res; 1998 Oct; 58(20):4682-7. PubMed ID: 9788622
[TBL] [Abstract][Full Text] [Related]
16. Generation of IL-2-dependent cytolytic T lymphocytes (CTLs) with altered TCR responses derived from antigen-dependent CTL clones.
Gullo CA; Esser MT; Fuller CL; Lam Braciale V
J Immunol; 1999 Jun; 162(11):6466-72. PubMed ID: 10352261
[TBL] [Abstract][Full Text] [Related]
17. Alloreactive T cells that do not require TCR and CD8 coengagement are present in naive mice and contribute to graft rejection.
Smith PA; Potter TA
J Immunol; 1998 Jun; 160(11):5382-9. PubMed ID: 9605138
[TBL] [Abstract][Full Text] [Related]
18. T cell-mediated, IFN-gamma-facilitated rejection of murine B16 melanomas.
Böhm W; Thoma S; Leithäuser F; Möller P; Schirmbeck R; Reimann J
J Immunol; 1998 Jul; 161(2):897-908. PubMed ID: 9670968
[TBL] [Abstract][Full Text] [Related]
19. NK and CTL recognition of a single chain H-2Dd molecule: distinct sites of H-2Dd interact with NK and TCR.
Chung DH; Dorfman J; Plaksin D; Natarajan K; Belyakov IM; Hunziker R; Berzofsky JA; Yokoyama WM; Mage MG; Margulies DH
J Immunol; 1999 Oct; 163(7):3699-708. PubMed ID: 10490965
[TBL] [Abstract][Full Text] [Related]
20. TCR internalization induced by peptide/MHC ligands requires the transmembrane domains of alphabeta chains of TCR, but not the expression of CD8 and Thy-1 molecules.
Lee MH; Min D; Sonn CH; Lee KN; Kim KE; Paik SG; Kim YS
Mol Cells; 1999 Dec; 9(6):617-24. PubMed ID: 10672928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
